Since 1993, 15 disease-modifying therapies have been approved by the FDA for the treatment of relapsing-remitting multiple sclerosis ... products and glatiramer acetate. Although more recently ...

BG-12 (dimethyl fumarate) is in development as an oral treatment for relapsing–remitting multiple sclerosis, which is commonly treated with parenteral agents (interferon or glatiramer acetate).

For patients suffering from multiple sclerosis (MS), becoming ... A study on the drug glatiramer acetate can relieve mothers of this concern during the breastfeeding period. A comparative study ...

The objective of this investigation was to examine treatment persistence with glatiramer acetate (GA) relative to available disease-modifying therapies (DMT) for multiple sclerosis (MS ...

Glatiramer acetate is an approved drug for relapsing-remitting multiple sclerosis (MS). An Article published Online First (www.thelancet.com) and in an upcoming edition of the Lancet shows that ...

Germany), was presented today at EAN congress and provided new insight on the use of COPAXONE® (glatiramer acetate or GA) by mothers with multiple sclerosis (MS) who are breastfeeding.

Today, the FDA issued a warning about the risk of anaphylaxis, a rare but life-threatening allergic reaction, linked to certain multiple sclerosis (MS) drugs, including glatiramer acetate ...

1.4 Interferon beta‑1b (Betaferon) is not recommended within its marketing authorisation as an option for treating multiple sclerosis. 1.5 These recommendations are not intended to affect treatment ...

This international Phase III trial in patients with relapsing-remitting multiple sclerosis (RRMS), is ... tolerability of 40mg COPAXONE ® (glatiramer acetate injection) administered three times ...

The US Food and Drug Administration (FDA) is adding the risk of anaphylaxis to a new boxed warning of glatiramer acetate, a medicine for multiple sclerosis (MS). The agency issued the warning ...

More information: Andrea Ines Ciplea et al, Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis—COBRA study ...

There were 35,312 MS patients with 12 months of follow-up including 12,144 (34.4%) patients on GA therapy; 21,927 patients were identified with 24 months of follow-up, including 7,386 (33.7%) on ...